Must-See Earnings Estimates for: Immunovant (NASDAQ:IMVT)

Earnings results for Immunovant (NASDAQ:IMVT)

Immunovant, Inc. is estimated to report earnings on 11/11/2020. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 6 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.33.

Immunovant last released its quarterly earnings results on August 12th, 2020. The reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.33) by $0.05. Immunovant has generated ($1.54) earnings per share over the last year. Immunovant has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Wednesday, November 11th, 2020 based off prior year’s report dates.

Analyst Opinion on Immunovant (NASDAQ:IMVT)

16 Wall Street analysts have issued ratings and price targets for Immunovant in the last 12 months. Their average twelve-month price target is $43.13, predicting that the stock has a possible downside of 8.32%. The high price target for IMVT is $63.00 and the low price target for IMVT is $27.00. There are currently 16 buy ratings for the stock, resulting in a consensus rating of “Buy.”

Immunovant has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 16 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $43.13, Immunovant has a forecasted downside of 8.3% from its current price of $47.04. Immunovant has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Dividend Strength: Immunovant (NASDAQ:IMVT)

Immunovant does not currently pay a dividend. Immunovant does not have a long track record of dividend growth.

Insiders buying/selling: Immunovant (NASDAQ:IMVT)

In the past three months, Immunovant insiders have bought more of their company’s stock than they have sold. Specifically, they have bought $12,730,850.00 in company stock and sold $0.00 in company stock. Only 0.24% of the stock of Immunovant is held by insiders. Only 33.94% of the stock of Immunovant is held by institutions.

Earnings and Valuation of Immunovant (NASDAQ:IMVT

Earnings for Immunovant are expected to decrease in the coming year, from ($1.43) to ($1.67) per share. The P/E ratio of Immunovant is -30.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Immunovant is -30.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

More latest stories: here